Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
Abstract: The invention relates to compounds of the formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof, wherein L, R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating abnormal cell growth, such as cancer in a mammal by administering the compounds of formula 1.
Type:
Grant
Filed:
May 27, 2005
Date of Patent:
September 29, 2009
Assignee:
Pfizer Inc.
Inventors:
Matthew A. Marx, Jinshan Chen, Susan LaGreca
Abstract: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
Type:
Grant
Filed:
January 4, 2007
Date of Patent:
September 22, 2009
Assignee:
Pfizer Limited
Inventors:
Nathan Anthony Logan Chubb, Mark Roger Cox, Jerome Sebastien Dauvergne, Richard Andrew Ewin, Christelle Lauret
Abstract: This invention relates to methods for cultivating Lawsonia intracellularis. In particular, the present invention provides improved methods for cultivating Lawsonia intracellularis by employing reducing agents other than molecular hydrogen; or alternatively, by employing a combination of one or more reducing agents with molecular hydrogen. This invention also relates to vaccines and diagnostic reagents prepared from Lawsonia intracellularis cultivated by employing the methods disclosed herein.
Abstract: Bicyclo-pyrazole compound of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, processes for their preparation, combinatorial libraries comprising a plurality of them and pharmaceutical compositions thereof, are herewith disclosed: the compounds of the invention are useful, in therapy, as protein kinase inhibitors, for instance in the treatment of cancer.
Type:
Application
Filed:
May 27, 2009
Publication date:
September 17, 2009
Applicant:
PFIZER ITALIA S.R.L.
Inventors:
Roberto Tonani, Simona Bindi, Daniele Fancelli, Valeria Pittala', Mario Varasi
Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.
Abstract: The present invention relates to a method of treating pain using a compound of formula (I), wherein Ar, R1, R3 and R3a are as defined herein. The invention also relates to certain novel compounds of formula (I).
Abstract: The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phospho-diesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain.
Abstract: The invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R11, N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
Type:
Grant
Filed:
May 20, 2004
Date of Patent:
September 8, 2009
Assignee:
Pfizer, Inc.
Inventors:
Samit Kumar Bhattacharya, Jinshan Chen, Richard Damian Connell, John Charles Kath, Goss S. Kauffman, Blaise S. Lippa, Joel Morris
Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.
Type:
Grant
Filed:
February 18, 2008
Date of Patent:
September 1, 2009
Assignee:
Pfizer Inc
Inventors:
Tanisha D. Blake, Bruce C. Hamper, Wei Huang, James R. Kiefer, Jr., Joseph B. Moon, Bradley E. Neal, Kirk L. Olson, Matthew J. Pelc, Barbara A. Schweitzer, Atli Thorarensen, John I. Trujillo, Steven R. Turner
Abstract: Compounds having a structure according to formula (I) where RA, RB, RC, RD, RE, and RF are as defined herein, are useful as prokinetic agents.
Type:
Grant
Filed:
May 2, 2006
Date of Patent:
September 1, 2009
Assignee:
Pfizer Inc.
Inventors:
Yaoquan Liu, Christopher Carreras, David C. Myles, Yong Li, Simon James Shaw, Hong Fu, Yue Chen, Hao Zheng, Yandong Li, Mark A. Burlingame
Abstract: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
Type:
Grant
Filed:
August 11, 2006
Date of Patent:
September 1, 2009
Assignee:
Pfizer Italia S.r.l.
Inventors:
Daniele Fancelli, Barbara Forte, Jürgen Moll, Mario Varasi, Paola Vianello
Abstract: The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
August 29, 2006
Publication date:
August 27, 2009
Applicant:
Pfizer Products Inc.
Inventors:
Thomas Bruno Lanni, Scott Edward Lazerwith, Susan Mary Kult Sheehan, Anthony Jerome Thomas
Abstract: A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arranged as generally orderly packed agglomerates, which are particularly useful in making pharmaceutical compositions. Such pharmaceutical compositions are also described, as well as methods to make crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, and methods of treating conditions characterized by an overexpression on nitric oxide from the inducible isoform of nitric oxide synthase using the S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.
Type:
Application
Filed:
December 5, 2008
Publication date:
August 27, 2009
Applicant:
Pfizer, Inc.
Inventors:
Lyle Brostrom, Ann Czyzewski, Vahid Zia, Ahmad Sheikh
Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
Type:
Grant
Filed:
August 22, 2007
Date of Patent:
August 25, 2009
Assignee:
Pfizer Inc
Inventors:
Ronald Biediger, Jie Chen, Daxin Gao, Robert Market, Chengde Wu
Abstract: The present invention provides compounds of formula (I) wherein X, Y, R1, R2 and R3 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.
Type:
Grant
Filed:
April 4, 2007
Date of Patent:
August 25, 2009
Assignee:
Pfizer, Inc.
Inventors:
Patricia Ann Basford, Peter Thomas Stephenson, Stefan Colin John Taylor, Anthony Wood
Abstract: This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula: wherein R1, R2 and R3, are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.
Type:
Application
Filed:
August 8, 2005
Publication date:
August 20, 2009
Applicant:
PFIZER INC.
Inventors:
Paul V. Rucker, Kevin D. Jerome, Shaun R. Selness, John E. Baldus, Li Xing
Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.
Type:
Grant
Filed:
June 19, 2006
Date of Patent:
August 18, 2009
Assignee:
Pfizer Inc.
Inventors:
Charlotte Moira Norfor Allerton, Andrew Douglas Baxter, Andrew Simon Cook, David Hepworth, Stephen Kwok-Fung Wong
Abstract: The present invention is directed to a new class of 4-oxo-benzonitriles, their use as androgen modulators, and to their use in the treatment of alopecia.
Type:
Grant
Filed:
February 8, 2005
Date of Patent:
August 18, 2009
Assignee:
Pfizer Inc.
Inventors:
Lain-Yen Hu, Huangshu Lei, Daniel Y. Du, Bruce A. Lefker